Reumatologia

Juvenile Idiopathic Arthritis.

The New England journal of medicine. 2025 Jul; 393(Jul):162-174. doi: 10.1056/NEJMra2402073. pii: .

Tropical pyomyositis.

Best practice & research. Clinical rheumatology. 2025 May; 39(May):102041. doi: 10.1016/j.berh.2025.102041. pii: S1521-6942(25)00009-9.

Autoimmune Connective Tissue Diseases: Systemic Lupus Erythematosus and Rheumatoid Arthritis.

Rheumatic diseases clinics of North America. 2025 May; 51(May):347-359. doi: 10.1016/j.rdc.2025.01.008. pii: S0889-857X(25)00008-0.

Newer Immunosuppressants for Rheumatologic Disease: Preoperative Considerations.

Rheumatic diseases clinics of North America. 2025 May; 51(May):383-395. doi: 10.1016/j.rdc.2025.01.010. pii: S0889-857X(25)00010-9.

Urine Protein Tests in Systemic Lupus Erythematosus: What Do They Mean?

The Journal of rheumatology. 2025 Apr; 52(Apr):308-315. doi: 10.3899/jrheum.2024-0910. pii: .

Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.

Annals of the rheumatic diseases. 2025 May; 84(May):664-679. doi: 10.1016/j.ard.2025.01.032. pii: S0003-4967(25)00181-5.

Expert Perspective: Diagnostic Approach to Differentiating Juvenile Dermatomyositis From Muscular Dystrophy.

Arthritis & rheumatology (Hoboken, N.J.). 2025 May; 77(May):506-520. doi: 10.1002/art.43057. pii: .

Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project.

Arthritis & rheumatology (Hoboken, N.J.). 2025 Apr; 77(Apr):477-489. doi: 10.1002/art.43038. pii: .

Recommendations for Aligned Nomenclature of Peripheral Nervous System Disorders Across Rheumatology and Neurology.

Arthritis & rheumatology (Hoboken, N.J.). 2025 Apr; 77(Apr):383-389. doi: 10.1002/art.43050. pii: .

The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis.

Annals of the rheumatic diseases. 2025 Apr; 84(Apr):538-546. doi: 10.1016/j.ard.2025.01.035. pii: S0003-4967(25)00185-2.

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.

The New England journal of medicine. 2025 May; 392(May):2013-2024. doi: 10.1056/NEJMoa2413449. pii: .

Arthritis related to parasitic infections.

Best practice & research. Clinical rheumatology. 2025 May; 39(May):102062. doi: 10.1016/j.berh.2025.102062. pii: S1521-6942(25)00030-0.

Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies.

Current opinion in rheumatology. 2025 May; 37(May):167-175. doi: 10.1097/BOR.0000000000001082. pii: .

TGFβ links EBV to multisystem inflammatory syndrome in children.

Nature. 2025 Apr; 640(Apr):762-771. doi: 10.1038/s41586-025-08697-6. pii: .

IgG4-related disease and other fibro-inflammatory conditions.

Nature reviews. Rheumatology. 2025 May; 21(May):275-290. doi: 10.1038/s41584-025-01240-x. pii: .

Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.

Rheumatology (Oxford, England). 2025 May; 64(May):2385-2394. doi: 10.1093/rheumatology/keae707. pii: .

The British Society for Rheumatology guideline for the management of foot health in inflammatory arthritis.

Rheumatology (Oxford, England). 2025 May; 64(May):2355-2368. doi: 10.1093/rheumatology/keaf071. pii: .

Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study.

The Lancet. Rheumatology. 2025 Apr; 7(Apr):e226-e229. doi: 10.1016/S2665-9913(24)00402-8. pii: S2665-9913(24)00402-8.

Rheumatologic complications of CAR-T Cell therapy. Experience of a single center.

Seminars in arthritis and rheumatism. 2025 Apr; 71(Apr):152610. doi: 10.1016/j.semarthrit.2024.152610. pii: S0049-0172(24)00250-6.

Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis.

Nature reviews. Rheumatology. 2025 Apr; 21(Apr):237-248. doi: 10.1038/s41584-025-01229-6. pii: .

What is rheumatoid factor? From screening to personalized management.

Rheumatology (Oxford, England). 2025 Mar; 64(Mar):ii9-ii14. doi: 10.1093/rheumatology/keaf003. pii: .

European expert recommendations for managing systemic sclerosis and its complications.

Nature reviews. Rheumatology. 2025 Mar; 21(Mar):133-134. doi: 10.1038/s41584-024-01205-6. pii: .

Brazilian recommendations for the management of tuberculosis infection in immune-mediated inflammatory diseases.

Advances in rheumatology (London, England). 2025 Mar; 65(Mar):18. doi: 10.1186/s42358-025-00449-4. pii: .

International Consensus Guidance for the Management of Glucocorticoid Related Complications in Neuromuscular Disease.

Muscle & nerve. 2025 Mar; 71(Mar):309-316. doi: 10.1002/mus.28328. pii: .

Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis.

Clinical rheumatology. 2025 Mar; 44(Mar):901-922. doi: 10.1007/s10067-025-07334-x. pii: .

Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel.

Rheumatology (Oxford, England). 2025 Feb; 64(Feb):561-573. doi: 10.1093/rheumatology/keae172. pii: .

British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.

Rheumatology (Oxford, England). 2025 Feb; 64(Feb):409-439. doi: 10.1093/rheumatology/keae152. pii: .

The 2024 British Society for Rheumatology guideline for management of systemic sclerosis.

Rheumatology (Oxford, England). 2024 Nov; 63(Nov):2956-2975. doi: 10.1093/rheumatology/keae394. pii: .

The 2024 APLAR Consensus on the Management of Lupus Nephritis.

International journal of rheumatic diseases. 2025 Jan; 28(Jan):e70021. doi: 10.1111/1756-185X.70021. pii: .

British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2024.

Rheumatology (Oxford, England). 2025 Jan; 64(Jan):74-90. doi: 10.1093/rheumatology/keae438. pii: .

Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.

JAMA. 2025 Feb; 333(Feb):498-508. doi: 10.1001/jama.2024.27154. pii: .

2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis.

Arthritis care & research. 2023 Aug; 75(Aug):1603-1615. doi: 10.1002/acr.25117. pii: .

Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults.

Annals of the rheumatic diseases. 2024 Nov; doi: 10.1136/ard-2024-226446. pii: ard-2024-226446.

Global RA treatment recommendations: An update from the various international societies.

Best practice & research. Clinical rheumatology. 2024 Nov; 102019. doi: 10.1016/j.berh.2024.102019. pii: S1521-6942(24)00090-1.

Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results.

Current opinion in rheumatology. 2024 Nov; 36(Nov):420-426. doi: 10.1097/BOR.0000000000001049. pii: .

Disease activity score for still's disease.

Clinical rheumatology. 2024 Nov; 43(Nov):3273-3283. doi: 10.1007/s10067-024-07127-8. pii: .

Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.

Annals of the rheumatic diseases. 2024 Nov; 83(Nov):1731-1747. doi: 10.1136/ard-2024-225854. pii: .

The 2024 British Society for Rheumatology guideline for management of systemic sclerosis-executive summary.

Rheumatology (Oxford, England). 2024 Nov; 63(Nov):2948-2955. doi: 10.1093/rheumatology/keae390. pii: .

Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline.

BMJ (Clinical research ed.). 2024 Oct; 387(Oct):e079830. doi: 10.1136/bmj-2024-079830. pii: .

EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.

Annals of the rheumatic diseases. 2024 Nov; 83(Nov):1614-1627. doi: 10.1136/ard-2024-225851. pii: .

EULAR recommendations for the treatment of systemic sclerosis: 2023 update.

Annals of the rheumatic diseases. 2024 Oct; doi: 10.1136/ard-2024-226430. pii: ard-2024-226430.

A clinical practice guideline for the management of the foot and ankle in rheumatoid arthritis.

Rheumatology international. 2024 Aug; 44(Aug):1381-1393. doi: 10.1007/s00296-024-05633-1. pii: .

2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis.

Advances in rheumatology (London, England). 2024 Jul; 64(Jul):52. doi: 10.1186/s42358-024-00392-w. pii: .

II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.

Advances in rheumatology (London, England). 2024 Jun; 64(Jun):48. doi: 10.1186/s42358-024-00386-8. pii: .

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

Arthritis & rheumatology (Hoboken, N.J.). 2024 Aug; 76(Aug):1182-1200. doi: 10.1002/art.42861. pii: .

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

Arthritis & rheumatology (Hoboken, N.J.). 2024 Aug; 76(Aug):1201-1213. doi: 10.1002/art.42860. pii: .

Juvenile Idiopathic Arthritis.

The New England journal of medicine. 2025 Jul; 393(Jul):162-174. doi: 10.1056/NEJMra2402073. pii: .

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.

The New England journal of medicine. 2025 May; 392(May):2013-2024. doi: 10.1056/NEJMoa2413449. pii: .

The safety of low-dose methotrexate for rheumatic diseases: looking beyond blood monitoring.

Rheumatology (Oxford, England). 2025 May; doi: 10.1093/rheumatology/keaf257. pii: keaf257.

Musculoskeletal manifestations in leprosy.

Best practice & research. Clinical rheumatology. 2025 May; 39(May):102039. doi: 10.1016/j.berh.2025.102039. pii: S1521-6942(25)00007-5.

Tropical pyomyositis.

Best practice & research. Clinical rheumatology. 2025 May; 39(May):102041. doi: 10.1016/j.berh.2025.102041. pii: S1521-6942(25)00009-9.

An update on the pathogenesis of idiopathic inflammatory myopathies.

Current opinion in rheumatology. 2025 May; 37(May):192-198. doi: 10.1097/BOR.0000000000001077. pii: .

Autoimmune Connective Tissue Diseases: Systemic Lupus Erythematosus and Rheumatoid Arthritis.

Rheumatic diseases clinics of North America. 2025 May; 51(May):347-359. doi: 10.1016/j.rdc.2025.01.008. pii: S0889-857X(25)00008-0.

Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.

Rheumatology (Oxford, England). 2025 May; 64(May):2385-2394. doi: 10.1093/rheumatology/keae707. pii: .

Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies.

Current opinion in rheumatology. 2025 May; 37(May):167-175. doi: 10.1097/BOR.0000000000001082. pii: .

Arthritis related to parasitic infections.

Best practice & research. Clinical rheumatology. 2025 May; 39(May):102062. doi: 10.1016/j.berh.2025.102062. pii: S1521-6942(25)00030-0.